News and Media

2016/09/06 – Quantum Genomics to Present at Rodman & Renshaw 18th Annual Conference in New York on September 13

12 September 2016
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that its Chief Executive Officer, Lionel Ségard, will present at the 18th Annual Rodman & Renshaw Global Investment […]

2016/06/30 – Quantum Genomics initiates Phase IIa trial for Heart Failure, the second strategic initiative for its BAPAI therapeutic platform

30 June 2016
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced the initiation of its Phase IIa multicentric clinical trial of GQC101, entitled QUID HF (QUantum Genomics […]

2016/06/28 – Quantum Genomics extends its collaboration agreement with its partner in animal health

28 June 2016
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announced that it has extended its collaboration agreement with its partner, a world leader in animal health […]

2016/05/31 – Quantum Genomics symposium at the European Meeting on Hypertension and Cardiovascular Protection

31 May 2016
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, will be taking part in the 26th European Meeting on Hypertension and Cardiovascular Protection, from the 10th to the 13th of […]